Thanks Hitesh for a lucid explanation of the impact of the latest approval.
The market seems to be considering abilify as an one time earning. Now another big approval in their fold the earnings should grow more homogeneous way.
Only thing left now is their own front end team in US, which they are already building. So their margins will improve going forward. This will ensure that the lumpiness in earnings due to the nature of generic business will reduce to certain extent.
Posts tagged All News
Alembic & Alembic Pharma (26-08-2015)
Rupee down 4 paise at 66.14 (26-08-2015)
The rupee today turned weak against the US dollar, after a brief recovery yesterday, falling by four paise to end at 66.14 on renewed demand for the American unit from importers amid global volatil...
UTI Mutual Fund launches “CanServe”- a new facility (26-08-2015)
![](http://10.0.1.104:85/_media/iifl/img/article/2015-07/07/full/1436269495-6492.jpg)
MMRDA sanctions Rs 35,400 cr for 118 km Mumbai metro network (26-08-2015)
Authority also approves DPRs for Andheri-E to Dahisar-E and Dahisar to DN Nagar corridors